
Dr. Edison Liu discusses the development of biomedical research institutions and Singapore's healthcare innovations in response to pandemics.
Dr. Edison Liu is a medical doctor turned cancer geneticist, whose work focuses on cancer genomics, breast cancer biology, and translational medicine. He has held senior leadership roles in biomedical research institutions in the United States and Asia, as the founding executive director of the Genome Institute of Singapore (GIS), and later the president and CEO of the Jackson Laboratory, one of the world's leading genetics research institutions. Along the way, he helped shape Singapore's biomedical landscape, led genomics research through crises like SARS, and expanded global position medicine efforts across Asia and North America. In Part 2, Dr. Edison Liu covers covers accountability and KPIs for Singapore’s biomedical initiative and how the 2003 SARS crisis validated translational research and GIS’s role, leading to recognition, embedding in MOH pandemic planning, and expanded work on H1N1/H5N1, Chikungunya, and Dengue. He shares that Singapore engineered healthcare as a discovery engine that supports economic welfare through pandemic control, precision medicine, and healthy aging, contrasting Singapore’s efficient population-based system with the US. He describes Singapore’s…
Explore listener stats, chart rankings, contacts and more on the Nucleate Singapore Pulse podcast page.